Bristol-Myers Squibb Company (BMY): Today's Featured Health Care Laggard

Editor's Note: TheStreet ratings do not represent the views of TheStreet's staff or its contributors. Ratings are established by computer based on metrics for performance (which includes growth, stock performance, efficiency and valuation) and risk (volatility and solvency). Companies with poor cash flow or high debt levels tend to earn lower ratings in our model

Bristol-Myers Squibb Company ( BMY) pushed the Health Care sector lower today making it today's featured Health Care laggard. The sector as a whole closed the day down 0.9%. By the end of trading, Bristol-Myers Squibb Company fell $0.79 (-1.7%) to $46.06 on light volume. Throughout the day, 6,897,564 shares of Bristol-Myers Squibb Company exchanged hands as compared to its average daily volume of 11,095,600 shares. The stock ranged in price between $46.03-$47.03 after having opened the day at $46.60 as compared to the previous trading day's close of $46.85. Other companies within the Health Care sector that declined today were: Vanda Pharmaceuticals ( VNDA), down 22.1%, USMD Holdings ( USMD), down 13.5%, Aoxing Pharmaceutical Company ( AXN), down 10.0% and Biodel ( BIOD), down 8.6%.
  • EXCLUSIVE OFFER: Jim Cramer's Protégé, Dave Peltier, only buys Stocks Under $10 that he thinks could potentially double. See what he's trading today with a 14-day FREE pass

Bristol-Myers Squibb Company, a biopharmaceutical company, discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products that help patients prevail over serious diseases worldwide. Bristol-Myers Squibb Company has a market cap of $76.3 billion and is part of the drugs industry. The company has a P/E ratio of 52.2, above the S&P 500 P/E ratio of 17.7. Shares are up 43.8% year to date as of the close of trading on Tuesday. Currently there are 8 analysts that rate Bristol-Myers Squibb Company a buy, 1 analyst rates it a sell, and 12 rate it a hold.

TheStreet Ratings rates Bristol-Myers Squibb Company as a buy. The company's strengths can be seen in multiple areas, such as its expanding profit margins, largely solid financial position with reasonable debt levels by most measures and solid stock price performance. We feel these strengths outweigh the fact that the company has had sub par growth in net income.

On the positive front, MediciNova ( MNOV), down 31.1%, Intercept Pharmaceuticals ( ICPT), down 16.4%, Oxygen Biotherapeutics ( OXBT), down 15.2% and Senesco Technologies ( SNTI), down 12.7% , were all gainers within the health care sector with Sarepta Therapeutics ( SRPT) being today's featured health care sector leader.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care ( RXD).

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

null

More from Markets

3 Things Investors Must Know for Monday

3 Things Investors Must Know for Monday

U.S. Earnings On Pace for Best Season in Two Decades but Tech Giants Await

U.S. Earnings On Pace for Best Season in Two Decades but Tech Giants Await

Alphabet Earnings and 4 Other Business Stories You Must Know Monday Morning

Alphabet Earnings and 4 Other Business Stories You Must Know Monday Morning

Alphabet Earnings, Bond Yields Rise, Akorn Plunges - 5 Things You Must Know

Alphabet Earnings, Bond Yields Rise, Akorn Plunges - 5 Things You Must Know

Global Stocks Slip as 3% 10-Year Yields, Bad Tech News Unsettle Markets

Global Stocks Slip as 3% 10-Year Yields, Bad Tech News Unsettle Markets